Information Provided By: 
Fly News Breaks for October 19, 2015
SHPG
Oct 19, 2015 | 06:51 EDT
JPMorgan analyst James Gordon recommends buying Shire on weakness after the company received a Complete Response Letter from the FDA over its application for approval of Lifitegrast for dry eye. The letter was "fairly well anticipated" by the market, Gordon tells investors in a research note. He continues to see a "very high chance of success" for the OPUS-3 Symptoms study to be reported next month. The analyst keeps an Overweight rating on Shire.
News For SHPG From the Last 2 Days
There are no results for your query SHPG
